{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atezolizumab&page=2", "query": { "intervention": "atezolizumab", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atezolizumab&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-07T17:53:42.978Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02298153", "title": "A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "NSCLC (Non-small Cell Lung Carcinoma)", "UC (Urothelial Cancer)" ], "interventions": [ { "name": "Epacadostat", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2015-01-27", "completion_date": "2017-11-08", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-06-07T17:53:42.978Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • Boston, Massachusetts + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02298153" }, { "nct_id": "NCT04984811", "title": "NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Non-Small Cell Lung Cancer", "Non-Small Cell Lung Carcinoma", "Nonsmall Cell Lung Cancer", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "efineptakin alfa", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NeoImmuneTech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2021-11-03", "completion_date": "2025-03", "has_results": false, "last_update_posted_date": "2024-03-05", "last_synced_at": "2026-06-07T17:53:42.978Z", "location_count": 22, "location_summary": "Mobile, Alabama • Cerritos, California • Norwich, Connecticut + 19 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Cerritos", "state": "California" }, { "city": "Norwich", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04984811" }, { "nct_id": "NCT05091567", "title": "A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Small-Cell Lung Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Lurbinectedin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 660, "start_date": "2021-11-18", "completion_date": "2026-08-13", "has_results": true, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-06-07T17:53:42.978Z", "location_count": 14, "location_summary": "Marietta, Georgia • Peoria, Illinois • Scarborough, Maine + 11 more", "locations": [ { "city": "Marietta", "state": "Georgia" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Scarborough", "state": "Maine" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05091567" }, { "nct_id": "NCT03693014", "title": "A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Cancer", "Melanoma Cancer", "Lung Cancer", "Bladder Cancer", "Renal Cancer", "Head/Neck Cancers" ], "interventions": [ { "name": "Stereotactic Body Radiotherapy", "type": "RADIATION" }, { "name": "Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "RADIATION", "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2018-10-01", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2025-10-06", "last_synced_at": "2026-06-07T17:53:42.978Z", "location_count": 10, "location_summary": "Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03693014" }, { "nct_id": "NCT03628716", "title": "CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "CV301", "type": "BIOLOGICAL" }, { "name": "Atezolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bavarian Nordic", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2018-09-18", "completion_date": "2021-02-02", "has_results": true, "last_update_posted_date": "2022-04-27", "last_synced_at": "2026-06-07T17:53:42.978Z", "location_count": 6, "location_summary": "Tampa, Florida • Louisville, Kentucky • Boston, Massachusetts + 2 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03628716" }, { "nct_id": "NCT03961698", "title": "Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Renal Cell Carcinoma" ], "interventions": [ { "name": "IPI-549 (eganelisib)", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Infinity Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2019-12-17", "completion_date": "2023-08-31", "has_results": false, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-06-07T17:53:42.978Z", "location_count": 24, "location_summary": "Chandler, Arizona • Tucson, Arizona • Fullerton, California + 20 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03961698" }, { "nct_id": "NCT04157985", "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Solid Tumors", "NSCLC", "Bladder Cancer", "HNSCC", "Renal Cancer", "Melanoma", "Anal Cancer", "Colorectal Cancer", "Cholangiocarcinoma", "Gastric Cancer", "Hepatocellular Carcinoma", "Merkel Cell Carcinoma", "Cervical Cancer" ], "interventions": [ { "name": "Continue PD-1/PD-L1 Inhibitors treatment", "type": "DRUG" }, { "name": "Discontinue PD-1/PD-L1-1 inhibitor", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Dan Zandberg", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 161, "start_date": "2019-11-15", "completion_date": "2025-11-07", "has_results": false, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-06-07T17:53:42.978Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04157985" }, { "nct_id": "NCT03942328", "title": "Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Stage III Hepatocellular Carcinoma AJCC v8", "Stage III Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8", "Unresectable Hepatocellular Carcinoma", "Unresectable Intrahepatic Cholangiocarcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Pheresis", "type": "PROCEDURE" }, { "name": "Pneumococcal 13-valent Conjugate Vaccine", "type": "BIOLOGICAL" }, { "name": "Therapeutic Autologous Dendritic Cells", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Esophagogastroduodenoscopy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2019-09-19", "completion_date": "2029-08-31", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-06-07T17:53:42.978Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03942328" }, { "nct_id": "NCT02951767", "title": "A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 119, "start_date": "2014-05-31", "completion_date": "2023-02-28", "has_results": true, "last_update_posted_date": "2024-03-28", "last_synced_at": "2026-06-07T17:53:42.978Z", "location_count": 47, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 35 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02951767" }, { "nct_id": "NCT03637764", "title": "Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasm" ], "interventions": [ { "name": "Isatuximab SAR650984", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2018-08-06", "completion_date": "2022-05-11", "has_results": true, "last_update_posted_date": "2023-07-10", "last_synced_at": "2026-06-07T17:53:42.978Z", "location_count": 3, "location_summary": "Santa Monica, California • Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03637764" } ] }